PATENT TRADEMARK OFFICE

lease type a plus sign (+) inside this box → 🕂 PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 051-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE (e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/052,589 TRANSMITTAL **Filing Date** January 18, 2002 **FORM First Named Inventor** Dianne M. Perez (to be used for all correspondence after initial filing) Group Art Unit 1632 Not yet assigned APR 2 3 2002 **Examiner Name** TER 1608 2900 26473/04200 Total Number of Pages in This Submission Attorney Docket Number **ENCLOSURES** (check all that apply) After Allowance Communication Assignment Papers Fee Transmittal Form (for an Application) to Group Appéal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Licensing-related Papers Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Affidavits/declaration(s) Provisional Application Status Letter Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request identify below): Terminal Disclaimer Return Receipt **Express Abandonment Request** Request for Refund Postcard Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Remarks APR 2 3 2002 Response to Missing Parts/ Incomplete Application Response to Missing Parts TECH CENTER 1600/2900 under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Individual name Pamela A. Docherty, Reg. No. 40,591 Signature Date CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: APRIL 15, 2002 FRICK Typed or printed name Wendi Frick Signature April 15,2002 Date

	PTO/SB/08B	(08-0)
ved for use through	10/31/2002, OMB 065	51-00

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
D a collection of information unless it contains a unit ONE

nio i apoi	WORK REGULETION AC	101 1333		spond to a collection of informatic	on unless it contains a valid C	JIMB CONTROL HUR	nber.	
Substitu	, , ~ ~ ute for form 1449B/l	РТО	& TRADENA	Complet if Kn wn				
	00114716		1001 001155	Application Number	10/052,589			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 18, 2002	主	-	
				First Named Inventor	Dianne M. Perez		٩٨	
			, <u></u>	Group Art Unit	1632	Z	\mathcal{D}	
	(use as man	y sheet	s as necessary)	Examiner Name	Not yet assigned	퓖	2	
Sheet	2	of	<u> </u>	Attorney Docket Number	26473/04200	20	_ ಲು	

		000				
		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	4.	PEREZ, ET AL., "Constitutive Activation of a Single Effector Pathway: Evidence for Multiple Activation States of a G Protein-Coupled Receptor" Molecular Pharmacology, 49:112-122 (1996).				
	5.	ZUSCIK, ET AL., "Cloning, Cell-Type Specificity, and Regulatory Function of the Mouse •1B-Adrenergic Receptor Promoter" Molecular Pharmacology, 56:1288-1297 (1999).				
	6.	SALLINEN, ET AL., "Genetic Alteration of *2C-Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedatomidine, a Subtype-Nonselective *2-Adrenoceptor Agonist" Molecular Pharmacology, 51:36-46 (1997).				
HWA, ET AL., "Synergism of Constitutive Activity in •1-Adrenergic Receptor Activation" Biochemistry, Vol. 36, No. 3, pp. 633-639, 1997.						
HOCHER, ET AL., "Endothelin-1 Transgenic Mice Develop Glomerulosclerosis, Interstitial Fibrosis, and Ren Cysts but not Hypertension" J. Clinc. Invest., Vol. 99, No. 6, March 1997, 1380-1389.						
	MILANO, ET AL., "Myocardial expression of a constitutively active •1B-Adrenergic receptor in transgenic m induces cardiac hypertrophy" Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 10109-10113, October 1994,					
ZUSCIK, ET AL., "Overexpression of the •1B-adrenergic receptor causes apoptotic neurodegeneration: system atrophy" Nature Medicine, Vol. 6, No. 12, December 2000, pp. 1388-1394.						
· · · · · · · · · · · · · · · · · · ·						
	:					

Examiner	Date	
Signature	Consider	ed

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box	→	+	
---	---	---	--

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of


C mpl t if Kn wn				
Application Number	10/052,589			
Filing Date	January 18, 2002			
First Named Inventor	Dianne M. Perez			
Group Art Unit	1632			
Examiner Name	Not yet assigned			
Attorney Docket Number	26473/04200			

ىلە	dry 1	U.S. PATENT DOCUMENTS								
" [E	xaminer nitials*	er Cite No.1 Number Kind Code2 (if known)		Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		1.	5,556,753		Bard, et al.	09-17-1996				
		2.	5,861,309		Bard, et al.	01-19-1999				
ŀ		3.	6,057,349		Cournoyer, et al.	05-02-2000				
ŀ			" ,			+				
Į							1			
Ļ							- 2 - 3			
ŀ						· ·				
ŀ						+	 			
H		-			<u> </u>	 	m % r			
t							20 w 111			
							1600/			
							0 0			
L							- 11 - 29 8 - D			
ŀ	 ↓					 	0 0			
-	_					+				
ŀ					- · · · · · · · · · · · · · · · · · · ·	+				
ŀ						+				

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.1	04-	F	oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	T	
		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6		
-							····	4_		
		 						╄		
		 			···			—		
		├					··	┿		
							<u>-</u>	+-		
		\vdash						+-		

Examiner		-	Date	
Signature			Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.